Peregrine Asset Advisers’s Bristol-Myers Squibb BMY Stock Holding History

Peregrine Asset Advisers’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.43M	Hold	24,747	–	–	0.31%	76
2026 Q1	$1.5M	Buy	24,747 +60	+0.2%	+$3.5K	0.4%	61
2025 Q4	$1.33M	Buy	24,687 +5,033	+26%	+$242K	0.38%	64
2025 Q3	$886K	Sell	19,654 -72	-0.4%	-$3.36K	0.27%	86
2025 Q2	$913K	Sell	19,726 -100	-0.5%	-$4.91K	0.28%	77
2025 Q1	$1.21M	Sell	19,826 -900	-4%	-$52.5K	0.45%	63
2024 Q4	$1.17M	Sell	20,726 -2,738	-12%	-$153K	0.43%	63
2024 Q3	$1.21M	Buy	23,464 +500	+2%	+$23.5K	0.42%	69
2024 Q2	$954K	Buy	22,964 +7,310	+47%	+$327K	0.38%	66
2024 Q1	$849K	Hold	15,654	–	–	0.34%	71
2023 Q4	$803K	Hold	15,654	–	–	0.39%	70
2023 Q3	$909K	Buy	+15,654	New	+$959K	0.47%	54
2022 Q1	–	Sell	-68,534	Closed	-$4.27M	–	113
2021 Q4	$4.27M	Buy	+68,534	New	+$4.02M	1.74%	23
2021 Q3	–	Sell	-63,764	Closed	-$4.26M	–	135
2021 Q2	$4.26M	Buy	+63,764	New	+$4.16M	1.94%	17
2017 Q4	–	Sell	-66,462	Closed	-$4.24M	–	107
2017 Q3	$4.24M	Sell	66,462 -14,501	-18%	-$847K	2.23%	19
2017 Q2	$4.51M	Buy	+80,963	New	+$4.41M	2.88%	11

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Peregrine Asset Advisers's BMY Position: Q2 2026 in Review

Peregrine Asset Advisers held its Bristol-Myers Squibb (BMY) position steady in Q2 2026 at 24,747 shares worth $1.43M. The position accounts for 0.31% of the portfolio, ranked #76.

Peregrine Asset Advisers first reported a position in BMY in Q2 2017 and has held it in 16 quarters since. The position peaked at $4.51M in Q2 2017. 2,508 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Peregrine Asset Advisers held 24,747 shares of Bristol-Myers Squibb worth $1.43M as of Q2 2026.
Peregrine Asset Advisers left its Bristol-Myers Squibb share count unchanged in Q2 2026.
Bristol-Myers Squibb made up 0.31% of Peregrine Asset Advisers's portfolio in Q2 2026, its #76 holding.
Peregrine Asset Advisers first reported a position in Bristol-Myers Squibb in Q2 2017 and has held it in 16 quarters since.
Peregrine Asset Advisers's Bristol-Myers Squibb position peaked at $4.51M in Q2 2017.
2,508 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Peregrine Asset Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.